Australia’s active vaccine safety system
New safety data for the Pfizer LP.8.1 COVID-19 vaccine show rates of side effects, medical attendance and impact of routine activities following vaccination are comparable to the previous variant Pfizer JN.1 vaccine.
The latest data, published by AusVaxSafety, show that most participants (74 per cent) experienced no side effects in the first 3 days following vaccination with the adult formulation (aged 12 years and older) of Pfizer LP.8.1 COVID-19 vaccine.
AusVaxSafety received responses from more than 2,200 Pfizer LP.8.1 COVID-19 vaccine recipients who participated in active vaccine safety surveillance via the AusVaxSafety monitoring system.
Among those who did experience side effects, local reaction (including pain, itching, redness and swelling at the injection site), fatigue, muscle/joint pain were most common.
These side effects were generally mild and short-lived, with most resolving within one day or less. Their impact on routine activities was low, with just 3 per cent of Pfizer LP.8.1 surveillance recipients reporting missing work, study or routine duties in the week following vaccination.
Reported medical attendance rates also remained low at 0.2 per cent.
These new safety data have been released as part of the ongoing AusVaxSafety COVID-19 vaccine surveillance program and will be updated monthly.
View the latest LP 8.1 COVID-19 vaccine safety data
